Bristol Myers Squibb’s Opdivo Brain Tumor Trial Fails Mid-Trial Assessment

Bristol Myers Squibb reported that the independent Data Monitoring Committee (DMC) had reviewed its CheckMate -548 Phase III trial of Opdivo (nivolumab) plus current standard of care in patients with newly diagnosed glioblastoma multiforme (GBM) with 06-methylguanine-DNA methyltransferase (MGMT) promoter methylation following surgical resection of the tumor.